Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Non-Standardized Pollen Allergenic Extract [EPC]
Carya Tomentosa Pollen is a non-standardized allergenic extract used for the diagnosis and treatment of Mockernut Hickory allergies. It belongs to the class of Non-Standardized Pollen Allergenic Extracts and is primarily used in subcutaneous immunotherapy.
Name
Carya Tomentosa Pollen
Raw Name
CARYA TOMENTOSA POLLEN
Category
Non-Standardized Pollen Allergenic Extract [EPC]
Drug Count
5
Variant Count
5
Last Verified
February 17, 2026
About Carya Tomentosa Pollen
Carya Tomentosa Pollen is a non-standardized allergenic extract used for the diagnosis and treatment of Mockernut Hickory allergies. It belongs to the class of Non-Standardized Pollen Allergenic Extracts and is primarily used in subcutaneous immunotherapy.
Detailed information about Carya Tomentosa Pollen
References used for this content
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Carya Tomentosa Pollen.
Carya Tomentosa Pollen, commonly known as Mockernut Hickory pollen, is a biological substance utilized in the field of clinical allergology. It is classified as a Non-Standardized Pollen Allergenic Extract [EPC]. This extract is derived from the male catkins of the Carya tomentosa tree, a member of the Juglandaceae family native to the Eastern United States. In clinical practice, this extract is used as both a diagnostic tool (via skin prick or intradermal testing) and a therapeutic agent (via Allergen Immunotherapy, or AIT).
As a non-standardized extract, Carya Tomentosa Pollen is typically measured in Protein Nitrogen Units (PNU) or as a Weight/Volume (w/v) ratio, rather than Bioequivalent Allergy Units (BAU). This distinction is critical for healthcare providers, as the potency of non-standardized extracts can vary between manufacturers and even between lots. The primary goal of using this extract is to identify patients with Type I hypersensitivity (IgE-mediated) to hickory pollen and to induce immunological tolerance in those with allergic rhinitis, allergic conjunctivitis, or allergic asthma triggered by this specific tree species.
According to the FDA's Center for Biologics Evaluation and Research (CBER), these extracts have been used for decades under historical safety profiles, though modern standardization efforts focus on identifying the specific major allergens—proteins that bind IgE in at least 50% of allergic individuals. For Carya Tomentosa, these proteins are complex and often show significant cross-reactivity with other members of the Carya genus (Pecans) and the Juglans genus (Walnuts).
The mechanism of Carya Tomentosa Pollen extract depends on its application. In diagnostic testing, the extract is introduced into the epidermis or dermis. If the patient has pre-existing IgE antibodies specific to Mockernut Hickory proteins, these antibodies—which are bound to the surface of mast cells—will cross-link upon contact with the allergen. This triggers a degranulation process, releasing histamine, leukotrienes, and prostaglandins, resulting in a localized 'wheal and flare' reaction within 15 to 20 minutes.
In therapeutic applications (Subcutaneous Immunotherapy or SCIT), the mechanism is far more complex and involves a fundamental 're-training' of the immune system. When administered in gradually increasing doses, the extract induces several key changes:
Unlike traditional small-molecule drugs, allergenic extracts like Carya Tomentosa Pollen do not follow standard pharmacokinetic pathways (absorption, distribution, metabolism, excretion) in the traditional sense. Instead, their 'disposition' is immunological.
Carya Tomentosa Pollen extract is FDA-indicated for the following:
Off-label uses are rare, though some clinicians may use these extracts in 'cluster' or 'rush' immunotherapy protocols, which involve more frequent injections to reach maintenance levels faster, though this carries a higher risk of systemic reactions.
Carya Tomentosa Pollen is available in several concentrated forms for clinical use:
> Important: Only your healthcare provider, typically an allergist or immunologist, can determine if Carya Tomentosa Pollen is right for your specific condition. The selection of specific allergens for a treatment vial is a highly individualized process based on your clinical history and diagnostic test results.
Dosage for Carya Tomentosa Pollen is highly individualized and must be determined by a qualified allergist. There is no 'standard' dose because the concentration depends on the patient's level of sensitivity.
Immunotherapy is divided into two phases:
Carya Tomentosa Pollen is generally considered safe for use in children, typically those aged 5 years and older. Dosing protocols for children are generally the same as for adults, as the immune system's response to the allergen is not strictly weight-dependent. However, the decision to start immunotherapy in a child must consider the child's ability to tolerate frequent injections and the potential for systemic reactions. It is rarely started in children under the age of 5 due to the difficulty of communicating symptoms of an impending systemic reaction.
No dosage adjustment is typically required for patients with renal impairment, as the allergenic proteins are not cleared by the kidneys. However, the patient's overall health and ability to tolerate a systemic reaction (and the medications used to treat it, like epinephrine) must be assessed.
No dosage adjustment is required for hepatic impairment.
Caution is advised in elderly patients. While there is no specific age-based dose reduction, older adults are more likely to have underlying cardiovascular disease, which increases the risk of complications if a systemic reaction occurs. The use of beta-blockers in this population is a significant concern.
Carya Tomentosa Pollen extract is strictly for professional use. It is administered via subcutaneous injection, usually in the posterior aspect of the upper arm.
If a dose is missed during the build-up phase, the next dose may need to be reduced or the previous dose repeated, depending on how much time has passed. If a dose is missed during the maintenance phase:
An 'overdose' in the context of immunotherapy refers to the administration of a dose higher than the patient's current tolerance level. This can lead to severe systemic reactions or anaphylaxis.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or the frequency of your injections without medical guidance.
Most patients undergoing immunotherapy with Carya Tomentosa Pollen will experience some form of local reaction. These are generally not dangerous but can be uncomfortable.
> Warning: Stop taking Carya Tomentosa Pollen and call your doctor immediately if you experience any of these symptoms, which may indicate the onset of anaphylaxis.
There are no known long-term 'toxic' effects of Carya Tomentosa Pollen extract, as it is a natural protein. However, the primary long-term risk is the development of new sensitivities or the rare risk of triggering an underlying autoimmune condition, though the latter is largely theoretical and not supported by robust clinical data. Most long-term effects are positive, such as a permanent reduction in allergy symptoms and a decreased risk of developing asthma in children with allergic rhinitis.
Carya Tomentosa Pollen extracts, like all allergenic extracts, carry a Black Box Warning regarding the risk of severe systemic reactions.
Report any unusual symptoms to your healthcare provider. Even a large local reaction should be reported, as it may be a precursor to a systemic reaction at the next, higher dose.
Carya Tomentosa Pollen extract is a potent biological product. Safety is paramount, and the following precautions must be strictly observed. This extract is never for self-administration. It must be used under the supervision of a physician who is equipped to handle life-threatening emergencies.
No FDA black box warnings for Carya Tomentosa Pollen. (Note: While many allergenic extracts carry a class-wide warning in clinical practice, some specific non-standardized labels may not have the boxed format, but the safety requirements remain identical. For the purposes of this guide, the class-wide warning for anaphylaxis is the primary safety concern.)
Carya Tomentosa Pollen does not typically cause sedation. However, if a patient experiences a systemic reaction or receives epinephrine, they should not drive or operate machinery until they are fully recovered and cleared by a medical professional.
There is no direct interaction between alcohol and the pollen extract. However, alcohol consumption can cause vasodilation and may theoretically increase the rate of allergen absorption or mask the early symptoms of an allergic reaction. It is generally advised to avoid alcohol for several hours after an injection.
Immunotherapy is typically discontinued if:
There is no 'withdrawal' syndrome associated with stopping Carya Tomentosa Pollen, but allergy symptoms may eventually return if the immune system was not sufficiently desensitized.
> Important: Discuss all your medical conditions with your healthcare provider before starting Carya Tomentosa Pollen.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. This includes eye drops and topical creams, as some may contain beta-blockers or steroids.
Carya Tomentosa Pollen belongs to the Juglandaceae family. Patients who are allergic to this extract are highly likely to show cross-sensitivity to:
Clinicians must be aware that if a patient is highly sensitive to one of these, they may react strongly to Carya Tomentosa Pollen even at low doses.
> Important: Your healthcare provider will evaluate your complete medical history before prescribing Carya Tomentosa Pollen.
Carya Tomentosa Pollen is classified by the FDA in Pregnancy Category C. This means there are no adequate and well-controlled studies in pregnant women.
There is no evidence that allergenic extract proteins pass into breast milk in any significant amount, nor is there evidence of harm to the nursing infant. Immunotherapy is generally considered safe to continue while breastfeeding. The benefits of controlling the mother's allergic asthma or rhinitis often outweigh the negligible risks.
As the extract consists of naturally occurring proteins that are processed by the immune system's cellular machinery rather than the kidneys, renal impairment does not affect the 'pharmacokinetics' of the drug. However, severe renal disease may limit the patient's ability to recover from a systemic reaction.
There are no specific adjustments or concerns for patients with hepatic impairment. The liver is not involved in the primary processing of allergenic extracts.
> Important: Special populations require individualized medical assessment. Always inform your allergist if you become pregnant or develop new health conditions during the course of your treatment.
Carya Tomentosa Pollen extract works through immunomodulation. It contains a mixture of proteins, including glycoproteins and enzymes, that act as antigens. When injected subcutaneously, these antigens are captured by Peripheral Dendritic Cells. These cells process the proteins and present them to Naive T-cells in the lymph nodes.
Under the influence of the gradually increasing doses, the T-cells differentiate into Regulatory T-cells (Tregs) instead of Th2 cells. These Tregs produce Interleukin-10 (IL-10), which signal B-cells to stop producing IgE (the allergy antibody) and start producing IgG4 (the blocking antibody). IgG4 competes with IgE for the allergen binding sites on mast cells and basophils, preventing the release of inflammatory mediators like histamine.
| Parameter | Value |
|---|---|
| Bioavailability | N/A (Subcutaneous local action) |
| Protein Binding | High (to specific IgE and IgG antibodies) |
| Half-life | Hours (for proteins) to Months (for immune memory) |
| Tmax | 15-30 minutes (for local skin reaction) |
| Metabolism | Cellular proteolysis by Antigen Presenting Cells |
| Excretion | Not renally or fecally excreted in significant form |
Carya Tomentosa Pollen is a Non-Standardized Pollen Allergenic Extract. It belongs to the broader category of Biologics. Related medications include other tree pollen extracts (e.g., Oak, Maple, Pecan) and standardized extracts like Grass or Dust Mite, which are measured in BAU/mL.
Common questions about Carya Tomentosa Pollen
Carya Tomentosa Pollen extract is primarily used for the diagnosis and treatment of allergies to Mockernut Hickory trees. In a diagnostic setting, it is used in skin prick or intradermal tests to confirm if a patient has an IgE-mediated sensitivity to this specific pollen. Therapeutically, it is used in allergen immunotherapy (allergy shots) to desensitize the patient's immune system over time. This treatment is intended for patients with allergic rhinitis, conjunctivitis, or asthma that is triggered by hickory pollen. By receiving gradually increasing doses, the body learns to tolerate the pollen, leading to fewer symptoms during allergy season.
The most common side effects are localized reactions at the site of the injection. These include redness, itching, and swelling, which can range from the size of a mosquito bite to several centimeters in diameter. These reactions usually appear shortly after the injection and resolve within a few hours, though some can be delayed by up to 24 hours. Some patients may also experience a temporary 'flare' of their typical allergy symptoms, such as sneezing or watery eyes. While these are common, any reaction that is larger than the palm of your hand should be reported to your doctor before your next dose.
It is generally recommended to avoid alcohol for several hours after receiving an injection of Carya Tomentosa Pollen. Alcohol causes vasodilation (widening of the blood vessels), which could theoretically speed up the absorption of the allergen into your bloodstream and increase the risk of a systemic reaction. Additionally, alcohol can mask the early warning signs of an allergic reaction, such as flushing or a rapid heartbeat. To ensure maximum safety, patients should remain sober and observant for at least the first few hours following their immunotherapy session. Always follow the specific guidance provided by your allergist.
Carya Tomentosa Pollen is generally not started during pregnancy due to the risk of anaphylaxis, which can be dangerous for both the mother and the developing fetus. However, if a woman is already on a stable maintenance dose and is tolerating the injections well, most allergists will allow her to continue the treatment throughout pregnancy. The dose is typically not increased during this time to minimize the risk of a reaction. If you are planning to become pregnant or find out you are pregnant while on immunotherapy, you must inform your allergist immediately to discuss a safe management plan.
For diagnostic purposes, the extract works almost immediately, producing a skin reaction within 15 to 20 minutes. For therapeutic immunotherapy, however, the process is much slower. Most patients do not experience a significant reduction in their allergy symptoms until they reach their 'maintenance dose,' which typically takes 3 to 6 months of weekly injections. Full clinical benefits are often not realized until the patient has been on maintenance therapy for a full year, covering at least one complete hickory pollen season. For long-lasting results, the treatment is usually continued for 3 to 5 years.
Yes, you can stop taking Carya Tomentosa Pollen injections suddenly without experiencing a 'withdrawal' syndrome, as it is not a drug that the body becomes physically dependent on. However, stopping the treatment before the recommended 3-5 year course is complete may result in your allergy symptoms returning over time. If you stop during the 'build-up' phase, you will likely receive no long-term benefit at all. If you need to pause your treatment due to illness or travel, your allergist will need to adjust your dose when you return to ensure it is still safe for you.
If you miss a dose of Carya Tomentosa Pollen, you should contact your allergist's office as soon as possible to reschedule. Do not attempt to 'double up' on your next dose. The safety of immunotherapy depends on the timing of the injections. If you are in the build-up phase and miss a dose by more than a few days, your doctor may need to repeat the last dose or even reduce it slightly to ensure you don't have a reaction. If you are in the maintenance phase, a delay of a week is usually fine, but longer delays will require a temporary dose reduction.
There is no scientific evidence to suggest that Carya Tomentosa Pollen extract causes weight gain. The extract consists of natural proteins and is administered in very small quantities subcutaneously. It does not contain hormones, steroids, or calories that would affect your metabolic rate or appetite. If you experience weight changes while on immunotherapy, it is likely due to other factors, such as the use of oral corticosteroids for asthma or other unrelated lifestyle changes. You should discuss any concerns about weight with your primary care physician.
Carya Tomentosa Pollen can be taken with most medications, but there are critical exceptions. You must inform your doctor if you are taking beta-blockers (often prescribed for high blood pressure, heart conditions, or migraines), as these can make an allergic reaction more dangerous and harder to treat. ACE inhibitors and MAO inhibitors also require caution. Most standard allergy medications, like antihistamines and nasal steroids, are fine to take during treatment, although antihistamines must be stopped several days before any skin testing to ensure the results are accurate.
Allergenic extracts like Carya Tomentosa Pollen are biological products rather than simple chemical drugs, so the term 'generic' does not apply in the traditional sense. However, multiple biological manufacturers produce Mockernut Hickory extracts. While they all contain the same basic pollen proteins, they are 'non-standardized,' meaning the potency can vary between different brands. For this reason, allergists generally prefer not to switch between different manufacturers' extracts once a patient has started treatment, as a new brand might be stronger and increase the risk of a reaction.